Article in American journal of hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors at 1 institution in 1 country.
Maria Armila RuizDivision of Hematology & Oncology, Department of Medicine, Comprehensive Sickle Cell Center, University of Illinois at Chicago, Chicago, Illinois, USA.ORCID 0000-0003-1190-4219
Binal N ShahDivision of Hematology & Oncology, Department of Medicine, Comprehensive Sickle Cell Center, University of Illinois at Chicago, Chicago, Illinois, USA.
Guohui RenDivision of Hematology & Oncology, Department of Medicine, Comprehensive Sickle Cell Center, University of Illinois at Chicago, Chicago, Illinois, USA.
David ShueyDivision of Hematology & Oncology, Department of Medicine, Comprehensive Sickle Cell Center, University of Illinois at Chicago, Chicago, Illinois, USA.
Richard D MinshallDepartments of Anesthesiology and Pharmacology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.
Victor R GordeukDivision of Hematology & Oncology, Department of Medicine, Comprehensive Sickle Cell Center, University of Illinois at Chicago, Chicago, Illinois, USA.ORCID 0000-0003-4725-7295
Santosh L SarafDivision of Hematology & Oncology, Department of Medicine, Comprehensive Sickle Cell Center, University of Illinois at Chicago, Chicago, Illinois, USA.ORCID 0000-0002-8584-4194
University of Illinois Chicago · US
Funding
Fibroblast Mediated Mechanisms of Pulmonary HypertensionR01HL142636 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MINSHALL, RICHARD D · 2019 to 2023
$2.0M
Pathways of Cell-Free Hemoglobin in Sickle Cell NephropathyR01HL153161 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SARAF, SANTOSH · 2020 to 2024
$2.0M
Cell-free Hemoglobin in Sickle Cell Acute Kidney InjuryR03HL146788 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SARAF, SANTOSH · 2019 to 2020
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Thrombomodulin and multiorgan failure in sickle cell anemia. · full record | OpenQuestion